Serum hepcidin concentrations and local hepcidin expression have been reported to increase in a variety of neoplasms, including lung cancer, breast cancer, renal carcinoma, prostate cancer, colorectal cancer, and acute leukaemia. This evidence concerns the gene HAMP and prostate cancer.